Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.
about
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenibPostinfarct Left Ventricular Remodelling: A Prevailing Cause of Heart FailureModeling and Simulation Approaches for Cardiovascular Function and Their Role in Safety AssessmentInduced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screeningComputer-based prediction of the drug proarrhythmic effect: problems, issues, known and suspected challengesThe Nuremberg Code subverts human health and safety by requiring animal modelingDrug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsTranslational Prospects and Challenges in Human Induced Pluripotent Stem Cell Research in Drug DiscoveryPET Metabolic Biomarkers for CancerCombination therapeutics in complex diseasesRecent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsCombination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitorsStem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injuryUse of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) to Monitor Compound Effects on Cardiac Myocyte Signaling Pathways.Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.Promiscuity and the conformational rearrangement of drug-like molecules: insight from the protein data bank.Cardiomyocyte autophagy and cancer chemotherapy.Cardiovascular Late Effects and Exercise Treatment in Breast Cancer: Current Evidence and Future DirectionsTargeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trialLapatinib for the treatment of breast cancer in the People's Republic of China.The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats.Identification of the molecular basis of doxorubicin-induced cardiotoxicity.Design and synthesis of minimalist terminal alkyne-containing diazirine photo-crosslinkers and their incorporation into kinase inhibitors for cell- and tissue-based proteome profiling.Assessing the translatability of in vivo cardiotoxicity mechanisms to in vitro models using causal reasoning.Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryConstitutive BDNF/TrkB signaling is required for normal cardiac contraction and relaxation.Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expressionAutomatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS)Physiologically relevant organs on chips.Cyclophosphamide-Induced Cardiomyopathy: A Case Report, Review, and Recommendations for Management.Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging.A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.Phosphorylation of apoptosis repressor with caspase recruitment domain by protein kinase CK2 contributes to chemotherapy resistance by inhibiting doxorubicin induced apoptosis.Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards.MicroRNA-34a Plays a Key Role in Cardiac Repair and Regeneration Following Myocardial Infarction.Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.Harnessing synthetic lethal interactions in anticancer drug discovery
P2860
Q21261282-50112181-07B7-4462-98FC-250E14981982Q26753845-E16B47A2-D53C-4866-B59F-B2CE65DBDD8FQ26801610-D1197DA2-9140-4285-B3B3-9E75ED9D02D2Q26828408-708F5BB2-422F-49A3-B6DA-C02CF6295652Q26861453-66A7C4CE-4441-4A93-94AB-DA524A6C01CEQ26866469-FFEE08F8-E22C-459A-8891-3416864D572AQ28071256-E1879ECC-B58B-4199-B2D6-44EFFC7F9E73Q28072402-08E0C565-A108-4047-9114-6EC12A8175F2Q28074449-9645384A-1AFB-4E11-9468-F87103B5023FQ28076891-2D86FA48-82E1-464E-BB5C-DA564449D93DQ28087776-B065C6C2-9189-430A-A060-48F5AC085F9DQ28484913-21929FCC-5CA6-4783-8D80-DC06A2F7C2C2Q28818235-C645FDBF-5DB0-4B5F-A5F9-3B8EB8392FE9Q30402943-432C7891-0373-4C1D-9A04-2BE144419B88Q30426853-E6256396-0E24-4420-8E23-9A4B4F8898FDQ30593372-1BB6B829-26C1-4C5C-89C8-B3D51DC96243Q30876537-4E9F63CF-601C-45EE-9E96-82B3A6FEBA5AQ33573823-AE3A87C9-CEB6-4B82-94C2-4ACC3EB3D973Q33907581-616DB0B9-DCD3-4200-B5B8-5E24D8D425A3Q33913901-961032EE-DF49-4844-A8FF-790D3D95311EQ34001004-EB77E8F7-0D40-4BC6-8095-BC3D3CE91A0EQ34016491-D9FE9EC2-60DC-49F9-88F2-C8F6B09B3C19Q34292469-EC422D3A-03FE-45EA-8E6D-6CB0E4208044Q34308627-E1D97E30-C2D3-47C0-B482-9AE3FC5C8550Q34765081-3F7241E1-19D2-4D3E-8670-B4C69AEAE3D1Q34980120-18E04C7F-8AD3-4620-BC08-A69843103ED7Q35039202-BA949941-1FEC-4D98-BEDC-885E3970AE1BQ35090013-876FD0FA-CE89-40DC-BD6D-CF00FE389F42Q35317533-E63CB457-09BF-4510-8626-85505A65AC28Q35673776-818C9C7F-683E-4F4D-94A6-688B9D742BD8Q35785080-3BCD78EB-BEC2-4C43-94AC-79190C41362BQ35927466-4C7E77A5-0FB6-4711-899E-B72B4F202535Q36003962-CA86B16F-FD12-4C04-9699-A547525A50B8Q36262416-D1E7C97D-A587-48B5-9A8D-D21637A8AF74Q36413878-E627C3A7-7E56-4092-8B55-2D18E8C30242Q36467485-14C56751-C878-425B-98CD-67A8970DAA01Q36566235-A729EBE3-D7D4-482D-AB6F-1195E5F5FECFQ36626642-C5404E70-B9D0-44B3-9A7C-678EC1ACDAD9Q36637796-B9667B3E-7490-4773-AB8E-3BB31D7F44A5Q36839571-6D1E1BB2-FAB5-4914-8175-4BA8013A002D
P2860
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiotoxicity of kinase inhib ...... l models to clinical outcomes.
@en
Cardiotoxicity of kinase inhib ...... l models to clinical outcomes.
@nl
type
label
Cardiotoxicity of kinase inhib ...... l models to clinical outcomes.
@en
Cardiotoxicity of kinase inhib ...... l models to clinical outcomes.
@nl
prefLabel
Cardiotoxicity of kinase inhib ...... l models to clinical outcomes.
@en
Cardiotoxicity of kinase inhib ...... l models to clinical outcomes.
@nl
P2860
P356
P1476
Cardiotoxicity of kinase inhib ...... al models to clinical outcomes
@en
P2093
Kyle L Kolaja
P2860
P2888
P304
P356
10.1038/NRD3252
P50
P577
2011-02-01T00:00:00Z